Day: May 25, 2023

BioSyent Declares Second Quarter 2023 Dividend

Written by Customer Service on May 25, 2023. Posted in Dividend Reports And Estimates.

MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing...

Report on Financial Results for the Three Months Ended March 31, 2023

Written by Customer Service on May 25, 2023. Posted in Earnings Releases And Operating Results.

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) — Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the three months ended March 31, 2023 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund’s focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company’s assets are located in Toronto, Brampton, Belleville,...

Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Written by Customer Service on May 25, 2023. Posted in Public Companies.

– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose – AUSTIN, TX and DURHAM, NC, May 25, 2023 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of complete dose-escalation data from the Phase 1A monotherapy clinical trial of SL-172154 in PROC. These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023. “We are excited to present data at ASCO that we...

Springwater Special Situations Corp. Receives Notice from Nasdaq Regarding Late Form 10-Q Filing

Written by Customer Service on May 25, 2023. Posted in Public Companies.

New York, New York, May 25, 2023 (GLOBE NEWSWIRE) — Springwater Special Situations Corp. (Nasdaq: SWSS) (the “Company”) announced today that the Nasdaq Stock Market LLC (“Nasdaq”), by letter dated May 25, 2023 (the “Notice”), notified the Company that it was not in compliance with Nasdaq’s continued listing standards because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Quarterly Report”). As reported in the Form 12b-25 filed by the Company with the Securities and Exchange Commission on May 15, 2023, the Company is still in the process of compiling required information to complete the Quarterly Report. As a result, the Company required additional time to compile and verify the data required to be included in the Quarterly Report. Under Nasdaq rules, the Company now...

Mettler-Toledo International Inc. Announces Webcast of Presentation at the Jefferies Healthcare Conference

Written by Customer Service on May 25, 2023. Posted in Public Companies.

Columbus, OH, May 25, 2023 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m Eastern Time. To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at investors.mt.com. A replay of the webcast will be available. METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences,...

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Written by Customer Service on May 25, 2023. Posted in Public Companies.

Media Release COPENHAGEN, Denmark; May 25, 2023Oral presentations will highlight epcoritamab–bysp in combination with rituximab–lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs existGenmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023. Presentations will include data from clinical trials evaluating the efficacy of epcoritamab...

UPDATE–VALHI ANNOUNCES QUARTERLY CASH DIVIDEND AND RESULTS OF ANNUAL STOCKHOLDER MEETING

Written by Customer Service on May 25, 2023. Posted in Dividend Reports And Estimates.

Dallas, Texas, May 25, 2023 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) announced today that its board of directors has declared a regular quarterly dividend of eight cents ($0.08) per share on its common stock, payable on June 22, 2023 to stockholders of record at the close of business on June 5, 2023. Valhi also announced that at its annual stockholder meeting held on May 25, 2023, its stockholders:elected each of Thomas E. Barry, Loretta J. Feehan, Terri L. Herrington, Kevin B. Kramer, W. Hayden McIlroy, Michael S. Simmons and Mary A. Tidlund as a director for a one-year term; adopted a resolution that approved, on a nonbinding advisory basis, the compensation of its named executive officers as disclosed in the proxy statement for the 2023 annual stockholder meeting; and approved, on a nonbinding advisory basis, an annual...

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Written by Customer Service on May 25, 2023. Posted in Public Companies.

Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation of this combination will focus on EC-naïve patients based on promising initial activity ERAS-007 in combination with cell cycle inhibitor palbociclib will not be pursued further in patients with RAS-mutated gastrointestinal (GI) malignancies Erasca to host investor event on June 5, 2023, at 4:30 PM Eastern Time SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced preliminary Phase 1b data for ERAS-007 combinations in patients with...

Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

Written by Customer Service on May 25, 2023. Posted in Mergers And Acquisitions.

DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined company Combined company will have commercial products and a library of development candidates, including two clinical stage programs DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorderSAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmaceuticals Corporation. The combined, publicly traded company will focus its efforts on increasing sales of Adamis’ commercial products and advancing DMK’s lead clinical stage compound, DPI-125, which is being studied as a potential novel treatment for opioid use disorder (OUD). The common stock...

Diana Shipping Inc. Announces Special Stock Dividend Distribution Date

Written by Customer Service on May 25, 2023. Posted in Dividend Reports And Estimates.

ATHENS, Greece, May 25, 2023 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that its previously announced special stock dividend payment to common shareholders of record as of April 24, 2023 (the “Record Date”) of an aggregate of 13,157 Series D Convertible Preferred Shares of OceanPal Inc. held by the Company, is now expected to be paid on or around June 9, 2023 (the “Stock Dividend Payment Date”). Other than the revised Stock Dividend Payment Date, no other changes are being made to the terms of the special stock dividend described in the OceanPal Inc. registration statement, including the Record Date and the election deadline. OceanPal Inc. has filed a registration statement with the U.S....

Day: May 25, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals